Stavudine versus zidovudine and the development of lipodystrophy

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 3, 2001, Pages 237-244

  Bogner, Johannes R ^a,d   Vielhauer, Volker ^a   Beckmann, Renate A ^a   Michl, Gerlinde ^a   Wille, Lutz ^b   Salzberger, Bernd ^c   Goebel, Frank D ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b BIELEFELD UNIVERSITY   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cholesterol; HIV; Lipodystrophy; Stavudine; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; AGE; ARTICLE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; VIRUS LOAD;

EID: 0035392909     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200107010-00004     Document Type: Article

References (22)

1. Fat distribution and metabolic changes in patients with HIV infection
2. Impaired glucose tolerance and protease inhibitors
3. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
4. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART)
5. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance
6. Protease inhibitor-associated hyperglycaemia
7. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: A cohort study
8. Hyperlipidemia under treatment with proteinase inhibitors
9. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
10. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
11. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer
12. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
13. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
14. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
15. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
16. Clinical factors related to the severity of fat redistribution in the HIV Outpatient Study (HOPS)
17. The Australian prevalence survey of lipodystrophy syndrome
18. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
19. Complete reversibility of severe nucleoside-induced lipodystrophy
20. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome
21. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART)
22. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection